Lung cancer

Balazs Halmos, Philip M. Boiselle, Daniel D. Karp

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer deaths in the world. In the U.S., approximately 170,000 cases and 155,000 deaths are predicted for 2002.1 Lung cancer accounts for 29% of all cancer deaths and causes more deaths than breast, colorectal and prostate cancer combined. While the prognosis of patients with lung cancer has improved over the past 20 years, overall it remains poor. Fewer than 15% of patients survive for more than 5 years. The poor prognosis is largely attributable to the fact that approximately 70% of lung cancer patients are diagnosed with mediastinal lymph node involvement, malignant effusion or distant metastases. In the US approximately 45 million people are current smokers and another 40-50 million are former smokers. Elimination of tobacco use as primary prevention of lung cancer should remain a priority for teenagers and young adults. However, considering the large pool of individuals at risk, lung cancer will undoubtedly remain a significant public health problem in the coming decades. Given our current inability to cure patients with metastatic disease, intensive efforts should be aimed at early identification and intervention. While screening and, more recently, chemoprevention have significantly impacted the incidence and survival of other cancers, such as breast, cervical and colorectal cancer, chemopreventive strategies for lung cancer have not shown clear benefits. In addition, radiographic screening is still controversial. In this review, we will provide a summary of the recent developments in the areas of molecular epidemiology, screening and chemoprevention with special emphasis on women.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalPrimary Care Update for Ob/Gyns
Volume10
Issue number3
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Lung Neoplasms
Chemoprevention
Cause of Death
Colorectal Neoplasms
Breast Neoplasms
Neoplasms
Molecular Epidemiology
Tobacco Use
Primary Prevention
Uterine Cervical Neoplasms
Young Adult
Prostatic Neoplasms
Public Health
Lymph Nodes
Neoplasm Metastasis
Survival
Incidence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Nursing(all)

Cite this

Lung cancer. / Halmos, Balazs; Boiselle, Philip M.; Karp, Daniel D.

In: Primary Care Update for Ob/Gyns, Vol. 10, No. 3, 05.2003, p. 87-94.

Research output: Contribution to journalReview article

Halmos, B, Boiselle, PM & Karp, DD 2003, 'Lung cancer', Primary Care Update for Ob/Gyns, vol. 10, no. 3, pp. 87-94. https://doi.org/10.1016/S1068-607X(03)00002-7
Halmos, Balazs ; Boiselle, Philip M. ; Karp, Daniel D. / Lung cancer. In: Primary Care Update for Ob/Gyns. 2003 ; Vol. 10, No. 3. pp. 87-94.
@article{fb39b88bff8f44e4a27ea5dd0af5523a,
title = "Lung cancer",
abstract = "Lung cancer is the most common cause of cancer deaths in the world. In the U.S., approximately 170,000 cases and 155,000 deaths are predicted for 2002.1 Lung cancer accounts for 29{\%} of all cancer deaths and causes more deaths than breast, colorectal and prostate cancer combined. While the prognosis of patients with lung cancer has improved over the past 20 years, overall it remains poor. Fewer than 15{\%} of patients survive for more than 5 years. The poor prognosis is largely attributable to the fact that approximately 70{\%} of lung cancer patients are diagnosed with mediastinal lymph node involvement, malignant effusion or distant metastases. In the US approximately 45 million people are current smokers and another 40-50 million are former smokers. Elimination of tobacco use as primary prevention of lung cancer should remain a priority for teenagers and young adults. However, considering the large pool of individuals at risk, lung cancer will undoubtedly remain a significant public health problem in the coming decades. Given our current inability to cure patients with metastatic disease, intensive efforts should be aimed at early identification and intervention. While screening and, more recently, chemoprevention have significantly impacted the incidence and survival of other cancers, such as breast, cervical and colorectal cancer, chemopreventive strategies for lung cancer have not shown clear benefits. In addition, radiographic screening is still controversial. In this review, we will provide a summary of the recent developments in the areas of molecular epidemiology, screening and chemoprevention with special emphasis on women.",
author = "Balazs Halmos and Boiselle, {Philip M.} and Karp, {Daniel D.}",
year = "2003",
month = "5",
doi = "10.1016/S1068-607X(03)00002-7",
language = "English (US)",
volume = "10",
pages = "87--94",
journal = "Primary Care Update for Ob/Gyns",
issn = "1068-607X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Lung cancer

AU - Halmos, Balazs

AU - Boiselle, Philip M.

AU - Karp, Daniel D.

PY - 2003/5

Y1 - 2003/5

N2 - Lung cancer is the most common cause of cancer deaths in the world. In the U.S., approximately 170,000 cases and 155,000 deaths are predicted for 2002.1 Lung cancer accounts for 29% of all cancer deaths and causes more deaths than breast, colorectal and prostate cancer combined. While the prognosis of patients with lung cancer has improved over the past 20 years, overall it remains poor. Fewer than 15% of patients survive for more than 5 years. The poor prognosis is largely attributable to the fact that approximately 70% of lung cancer patients are diagnosed with mediastinal lymph node involvement, malignant effusion or distant metastases. In the US approximately 45 million people are current smokers and another 40-50 million are former smokers. Elimination of tobacco use as primary prevention of lung cancer should remain a priority for teenagers and young adults. However, considering the large pool of individuals at risk, lung cancer will undoubtedly remain a significant public health problem in the coming decades. Given our current inability to cure patients with metastatic disease, intensive efforts should be aimed at early identification and intervention. While screening and, more recently, chemoprevention have significantly impacted the incidence and survival of other cancers, such as breast, cervical and colorectal cancer, chemopreventive strategies for lung cancer have not shown clear benefits. In addition, radiographic screening is still controversial. In this review, we will provide a summary of the recent developments in the areas of molecular epidemiology, screening and chemoprevention with special emphasis on women.

AB - Lung cancer is the most common cause of cancer deaths in the world. In the U.S., approximately 170,000 cases and 155,000 deaths are predicted for 2002.1 Lung cancer accounts for 29% of all cancer deaths and causes more deaths than breast, colorectal and prostate cancer combined. While the prognosis of patients with lung cancer has improved over the past 20 years, overall it remains poor. Fewer than 15% of patients survive for more than 5 years. The poor prognosis is largely attributable to the fact that approximately 70% of lung cancer patients are diagnosed with mediastinal lymph node involvement, malignant effusion or distant metastases. In the US approximately 45 million people are current smokers and another 40-50 million are former smokers. Elimination of tobacco use as primary prevention of lung cancer should remain a priority for teenagers and young adults. However, considering the large pool of individuals at risk, lung cancer will undoubtedly remain a significant public health problem in the coming decades. Given our current inability to cure patients with metastatic disease, intensive efforts should be aimed at early identification and intervention. While screening and, more recently, chemoprevention have significantly impacted the incidence and survival of other cancers, such as breast, cervical and colorectal cancer, chemopreventive strategies for lung cancer have not shown clear benefits. In addition, radiographic screening is still controversial. In this review, we will provide a summary of the recent developments in the areas of molecular epidemiology, screening and chemoprevention with special emphasis on women.

UR - http://www.scopus.com/inward/record.url?scp=0038627502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038627502&partnerID=8YFLogxK

U2 - 10.1016/S1068-607X(03)00002-7

DO - 10.1016/S1068-607X(03)00002-7

M3 - Review article

AN - SCOPUS:0038627502

VL - 10

SP - 87

EP - 94

JO - Primary Care Update for Ob/Gyns

JF - Primary Care Update for Ob/Gyns

SN - 1068-607X

IS - 3

ER -